ABIVAX Société Anonyme
ABVXHealthcareNASDAQBiotechnology · Last scanned Jul 18, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, ABIVAX Société Anonyme focuses on Biotechnology services and products. ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic. With a market capitalization of $11.91B, it sits in large-cap territory. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease.
Market Cap
$11.91B
Beta
-0.21
P/E (TTM)
—
P/E (Fwd)
-41.87
EPS (TTM)
$-5.21
EPS (Fwd)
$-3.26
ROE
-157.1%
ROA
-44.6%
Cash
$491.6M
Total Debt
$34.2M
Free CF
-$114.5M
52W Change
1273.4%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $491.6M in cash comfortably exceeding the $34.2M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$114.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -157.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The relatively low beta of -0.21 suggests ABVX is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, ABVX has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ABVX's risk profile alongside its fundamentals and technical indicators provides a more complete picture.